表紙
市場調査レポート

中国の血液製剤産業の分析

Research Report on China Blood Product Industry, 2011-2016

発行 China Research and Intelligence 商品コード 355895
出版日 ページ情報 英文 50 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=106.02円で換算しております。
Back to Top
中国の血液製剤産業の分析 Research Report on China Blood Product Industry, 2011-2016
出版日: 2016年04月07日 ページ情報: 英文 50 Pages
概要

中国国内には現在、血液製剤メーカーが33社存在していますが、実際に生産に従事しているのは20社に限られています。他方、中国の総人口が14億人だということを踏まえれば、血液製剤の潜在的な需要規模は12,000トンに達しますが、実際の需要量は8,000トン、そして中国国内での実際の供給量は5,000トンに留まっています。中国の場合、血漿の供給量が限られていることが最大の課題で、血液製剤メーカーは献血拠点の増設により供給量の確保を目指しています。今後は、血漿供給量の制約が緩むのに合わせて、メーカー間競争も研究開発 (R&D) 能力や販売能力を巡るものへと変化していくでしょう。

当レポートでは、中国国内の血液製剤産業について分析し、現在の産業構造・傾向やこれまでの発展経路、政府の政策、市場規模の推移と見通し (過去・今後5年間分)、主要企業のプロファイル、市場競争の状態などについて調査・推計しております。

第1章 血液製剤の概要

  • 定義
  • 特徴
  • 分類
  • 血液製剤関連の産業政策
    • 所轄官庁
    • 企業設立に関する政策
    • 原材料調達に関する政策
    • 血液製剤の生産に関する政策
    • 血液製剤の流通に関する政策
  • 中国の血液製剤産業の概況
    • 規制政策
    • 血液の利用率
    • 業界の特徴

第2章 世界の血液製剤産業の概況 (過去5年間分)

  • 産業概要
    • 発展過程
    • 競争パターン
    • 供給構造
    • 需要構造
  • 世界 (中国以外) の主な血液製剤メーカー
    • Baxter International
    • CSL Behring
    • Grifols SA

第3章 中国の血液製剤産業の需給状況 (過去5年間分)

  • 発展過程
  • 参入障壁
    • 政策障壁
    • 血液供給源の障壁
    • 技術・品質管理能力
  • 供給状況
    • 現在の生産状況:概要
    • 中国国内の主要な血液製剤メーカー
    • アルブミンの生産能力・生産量
    • 免疫グロブリンの生産能力・生産量
    • 凝固因子の生産能力・生産量
  • 需要状況
    • アルブミン
    • 免疫グロブリン
    • 凝固因子

第4章 中国の血液製剤産業の主要企業 (過去5年間分)

第5章 中国の血液製剤産業の動向予測 (今後5年間分)

  • 供給量の予測
    • 血漿供給量の予測
    • ロット引き渡し量の予測
    • 生産能力の拡張見通し
  • 需要量の予測
    • 需要動向の予測
    • 市場規模の予測
  • 市場競争の予測
    • 人気の高い製品の予測
    • 競争パターンの予測

図表一覧

目次
Product Code: 1604337

Blood products made by segregating and purifying all kinds of proteins in the blood plasma consists of albumin, immunoglobulin, thrombinogen and other products. China's enterprises mainly produce 9 kinds of products in the first three categories.

The high concentration rate of the global blood product market is embodied in the three companies of developed countries accounting for more than 80% of the global market. The current global blood market remains relatively stable, of which the emerging economy is the main motivation of growth.

By the end of 2015, there were 33 blood product manufacturing enterprises certified by the government in China, but in fact, only 20 of them were in production. Since 2012, mergers and acquisitions are common in China's blood product industry. For example, Jiangxi Boya Bio-Pharmaceutical Co., Ltd. acquired partial stock rights of Zhejiang Haikang Biologicals Co., Ltd. Beijing Tiantan Biological Products Co., Ltd. purchased Chengdu Rosen Pharmaceutical Co., Ltd. Watson Biological Company acquired Hebei Docan Pharmaceutical Co., Ltd. Shanghai RAAS Blood Products Co., Ltd. purchased Zhengzhou Banghe Pharmaceutical Co., Ltd. China National Biotec Group acquired Guiyang Qianfeng Biological Products Co., Ltd. and Xi'an Huitian Blood Products Co., Ltd. Humanwell Healthcare Group Co., Ltd. purchased Wuhan Rui De Biological Products Co., Ltd.

In 2015, 8,000 tons of blood plasma was needed to meet the demand of Chinese market, and the actual supply was only 5,000 tons. For example, the demand for blood products of about 1.4 billion population of China should be 12,000 tons calculated according to per capita demand of the normal blood products of the World Health Organization, which is far more than the actual supply of China.

In China's blood product industry, the scale of the blood plasma has been the main bottleneck restricting the development of blood product industry. The quality and quantity of plasma stations are of vital importance.

In 2001, Chinese government announced that no new blood product manufacturing enterprises would be approved to ensure the safety of blood and its products, and block the spread of HIV through collection and supply of blood .

In 2008, Chinese government formulated the regulations that the plasma collection regions should guarantee the quantity of the plasma donors, which can satisfy no less than 30 tons' collection of source plasma.

In 2011, Guizhou government announced the program of adjusting the settings of blood services. The plasma collection stations decreased from 20 to 4, of which Hualan Biological Engineering Co., Ltd., the blood product giant, suffered the most. The plasma stations of Guizhou Province decreased from 6 to 1, having reduced half of the corporate source plasma supply.

Lack of the local blood products, but Chinese government has issued strict regulations on the import of blood products. Only human serum albumin and three kinds of thrombinogen are allowed to be imported.

In recent years, the competitiveness of China's blood product market has been mainly determined by the amount of blood plasma resources. Under the tense condition of source plasma supply, blood product manufacturing enterprises will obtain more space for survival and development with more blood plasma stations and source plasma.

On June 1, 2015, China National Development and Reform Commission released the highest price limit on blood products, and companies can name their own prices. In the first quarter of 2016, the price of fibrinogen and tetanus immunoglobulin in Chinese market increases by 80%-130%, and the price of intravenous gammaglobulin increases by 10%-20%. In addition to the relaxed price regulations, another support policy is to gradually release the auditing of plasma collection stations. At the beginning of 2013, Chinese government released the auditing standards for plasma collection stations. By the end of 2013, there had been no more than 160 plasma collection stations in China. There were more than 200 plasma collection stations at the end of 2015. In spite of the most plasma collection stations, Shanghai RAAS Blood Products Co. Ltd. had possessed only 30 plasma collection stations in operation by the end of 2015.

In the long run, the competitiveness of blood product manufacturing enterprises mainly depends on the ability of research & development and sales. In a few years, the tense situation of China's raw blood plasma's supply will be eased. Only enterprises with strong ability of research & development and sales and a sound product line can win the competition.

There are only two channels for overseas blood product enterprise to enter Chinese market. One is to export products to China directly. The other one is to enter Chinese market indirectly through such means as equity acquisition.

The report is accomplished on the basis of deep market research. Through this report, the readers shall acquire the following information:

  • Current Situation of the Global Blood Product Industry
  • Development History and Current Situation of China's Blood Products
  • Government Policies of China's Blood Product Industry
  • Niche Products' Current Situation of China's Blood Product
  • Market Competition of China's Blood Product Industry
  • China's Major Blood Product Enterprises and Their Operation Status
  • Development Trend of China's Blood Product Industry

The Following Enterprises and People Are Recommended to Purchase This Report:

  • Blood Product Manufacturing Enterprises
  • Blood Product Regulatory Agency
  • Investors /Research Agencies Focusing on Blood Product Industry

Table of Contents

1. Introduction of Blood Products

  • 1.1. Definition
  • 1.2. Characteristics
  • 1.3. Classification
    • 1.3.1. Albumin
    • 1.3.2. Immune Globulin
    • 1.3.3. Coagulation Factors
    • 1.3.4. Other Categories
  • 1.4. Industrial Policies on Blood Product
    • 1.4.1. Industrial Competent Departments
    • 1.4.2. Policies on Enterprise Establishment
    • 1.4.3. Policies on Raw Material Purchasing
    • 1.4.4. Policies on Blood Product Production
    • 1.4.5. Policies on Blood Product Circulation
  • 1.5. Overview on China Blood Product Industry
    • 1.5.1. Regulatory Policies
    • 1.5.2. Blood Utilization Ratio
    • 1.5.3. Industry Characteristics

2. Overview of Global Blood Product Industry, 2011-2015

  • 2.1. Industry Overview
    • 2.1.1. Development Process
    • 2.1.2. Competition Pattern
    • 2.1.3. Supply Status
    • 2.1.4. Demand Status
  • 2.2. Major Blood Product Manufacturers in the Globe (Except China)
    • 2.2.1. Baxter International
    • 2.2.2. CSL Behring
    • 2.2.3. Grifols SA

3. Supply and Demand Status of China Blood Product Industry, 2011-2015

  • 3.1. Development Process
  • 3.2. Barriers to Entry
    • 3.2.1. Policy Barriers
    • 3.2.2. Blood Source Barrier
    • 3.2.3. Technology and Quality Control Capability
  • 3.3. Supply
    • 3.3.1. Overview on Production Status
    • 3.3.2. Major Blood Product Manufacturers in China
    • 3.3.3. Production Capacity and Output Volume of Albumin
    • 3.3.4. Production Capacity and Output Volume of Immune Globulin
    • 3.3.5. Production Capacity and Output Volume of Coagulation Factor
  • 3.4. Demand Status
    • 3.4.1. Albumin
    • 3.4.2. Immune Globulin
    • 3.4.3. Coagulation Factors

4. Major Enterprises of China Blood Product Industry, 2011- 2015

  • 4.1. Shanghai RAAS Blood Products Co. Ltd.
    • 4.1.1. Enterprise Profile
    • 4.1.2. Production Capacity
  • 4.2. Hualan Biological Engineering Co., Ltd.
  • 4.3. Beijing Tiantan Biological Products Co., Ltd. (Subsidiary of China National Biotec Group Company Limited)
  • 4.4. Guangdong Shuanglin Bio-pharmaceutical Co., Ltd.
  • 4.5. Jiangxi Boya Bio-pharmaceutical Co., Ltd.
  • 4.6. Hunan Nanyue Pharmaceutical Co., Ltd.
  • 4.7. Wuhan Rui De Biological Products Co., Ltd.
  • 4.8. Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd.
  • 4.9. Green Cross Biological Products Co., Ltd.
  • 4.10. Guiyang Qianfeng Biological Products Co., Ltd.
  • 4.11. Anhui Da'an Biological Products Co., Ltd.
  • 4.12. Shenzhen Weiguang Biological Products Co., Ltd.
  • 4.13. Shandong Taibang Products Co., Ltd.
  • 4.14. Subordinate Institutions of Biological Products of China National Biotec Group

5. Forecast on Development of China Blood Product Industry, 2016-2020

  • 5.1. Supply Forecast
    • 5.1.1. Forecast on Plasma Volume
    • 5.1.2. Forecast on Lot Release
    • 5.1.3. Forecast on Production Capacity Expansion
  • 5.2. Demand Forecast
    • 5.2.1. Demand Trend Prediction
    • 5.2.2. Prediction of Market Size
  • 5.3. Forecast on Market Competition
    • 5.3.1. Forecast on Popular Products
    • 5.3.2. Forecast on Competition Pattern

Selected Charts

  • Chart Common Varieties and Functions of Albumin
  • Chart Common Varieties and Functions of Immune Globulin
  • Chart Common Varieties and Functions of Coagulation Factors
  • Chart Varieties and Functions of Other Blood Products
  • Chart Important Policies of China Blood Product Industry
  • Chart Top 5 Blood Product Enterprises in the World, 2015
  • Chart Global Blood Product Plasma Volume and Forecast, 2009- 2020
  • Chart Global Blood Product Market Scale and Forecast, 2009-2020
  • Chart Market Share by Region in the Globe
  • Chart Market Share by Category in the Globe
  • Chart Sales Scale of Baxter International Blood Products, 2011-2015
  • Chart Sales Scale of CSL Behring Blood Products, 2011-2015
  • Chart Sales Scale of Grifols Blood Products, 2011-2015
  • Chart Blood Product Plasma Volume in China, 2009-2015
  • Chart Lot Release Volume of Blood Products in China, 2009-2015
  • Chart Major Blood Product Manufacturers in China
  • Chart Lot Release Volume of Albumin Products in China, 2009- 2015
  • Chart Lot Release Volume of Immune Globulin Products in China, 2009-2015
  • Chart Lot Release Volume of Coagulation Factor Products in China, 2009-2015
  • Chart Market Scale of China Blood Products, 2011-201528
  • Chart Market Scale of Albumin Blood Products in China, 2011-2015
  • Chart Market Scale of Immune Globulin Blood Products in China, 2011-2015
  • Chart Market Scale of Coagulation Factor Blood Products in China, 2011-2015
  • Chart Products of Shanghai RAAS Blood Products Co. Ltd.
  • Chart Plasma Volume of Shanghai RAAS Blood Products Co. Ltd., 2011-2015
  • Chart Plasma Collecting Stations Newly Approved by the Chinese after 2009
  • Chart Forecast on Plasma Volume in China, 2016-2020
  • Chart Forecast on Lot Release of China Blood Products, 2016-2020
  • Chart Comparison of Annual Blood Product Consumption Per Capita Between Developed Countries and China, 2015
  • Chart Forecast on the Market Scale of Blood Products in China, 2016-2020
  • Chart Forecast on the Market Scale of Albumin Products in China, 2016-2020
  • Chart Forecast on the Market Scale of Immune Globulin Products in China, 2016- 2020
  • Chart Forecast on the Market Scale of Coagulation Factor Products in China, 2016-2020
Back to Top